Here, we identified an autophagic vulnerability in cancers with BAP1 mutations involving the oncogenic tyrosine kinase SRC and the autophagy protein BECN1 that can be therapeutically targeted, opening the possibility of novel treatments specific for tumors with BAP1 loss. This evidence concerns the gene BECN1 and cancer.